Drug intelligence / Profile preview

AGY

Development stage: Unknown
Lead developer: IGY Immune Technologies & Life Sciences
Modality: Antibody-Based Therapeutics
Administration: Oral

Overview

AGY is an orally administered antibody (IgY) derived from the egg yolks of super immunized laying hens. Developed by Igy Inc., it is formulated into capsules and is being investigated for the prevention of symptoms in individuals with Celiac Disease. Its mechanism of action involves binding to gluten proteins in the small intestine, thereby preventing the inflammatory response and recurrence of symptoms associated with gluten exposure. AGY is classified as a natural health product and a dietary supplement.

Other names: IgY

Targets

Gluten

Beyond the preview

Go deeper on AGY.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGY.

Explore the full profile